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of	 patient	 derived	 tumor	 xenograft	 (PDX)	 models	 for	 cancer	 research.	 PDX	 models	
mostly	retain	the	principal	histological	and	genetic	characteristics	of	their	donor	tumor	
and	remain	stable	across	passages.	These	models	have	been	shown	to	be	predictive	of	
clinical	 outcomes	 and	 are	 being	 used	 for	 preclinical	 drug	 evaluation,	 biomarker	
identification,	 biological	 studies,	 and	 personalized	 medicine	 strategies.	 This	 paper	
summarizes	 the	 current	 state	of	 the	art	 in	 this	 field	 including	methodological	 issues,	





PDX	models	are	 increasingly	used	 in	 translational	 cancer	 research.	These	models	are	
useful	 for	 drug	 screening,	 biomarker	 development	 and	 the	 preclinical	 evaluation	 of	
personalized	medicine	 strategies.	 This	 review	 provides	 a	 timely	 overview	 of	 the	 key	









(USA)	 in	 the	 70s	 following	 a	 nearly	 three-decade	 period	 in	 which	 screening	 of	 new	
drugs	 was	 performed	 in	 rapidly	 growing	 murine	 models.	 Over	 the	 last	 40	 years,	 a	
number	of	studies	have	established	basic	methodology	and	a	systematic	approach	for	
preclinical	 testing	of	anticancer	agents	both	 in	 vitro	 and	 in	 vivo	 (1,	2).	Currently,	 the	
NCI-60	 cancer	 cell	 line	 panel	 represents	 the	 best	 characterized	 and	most	 frequently	
used	 collection	 of	 human	 cancer	 models	 utilized	 for	 in	 vitro	 drug	 screening	 and	
development	 (3).	 These	 cells	 were	 derived	 from	 cancer	 patients	 and	 have	 been	
adapted	 to	grow	 indefinitely	 in	 artificial	 culture	 conditions.	Xenografts	developed	by	




important	 limitations	 in	preclinical	drug	development.	The	most	relevant	 is	their	 lack	
of	 predictive	 value	 with	 regards	 to	 activity	 in	 specific	 cancer	 types	 in	 clinical	 trials.	
While	in	general,	agents	active	in	at	least	one	third	of	the	preclinical	models	explored	
to	 date	 showed	activity	 in	 phase	 II	 clinical	 trials,	 there	has	 been	poor	 prediction	 for	
activity	 in	 specific	 disease	 entities,	 except	 in	 lung	 cancer	 (4).	 While	 the	 underlying	
cause	of	 this	 limited	predictive	 value	 is	not	 fully	understood,	 evidence	 suggests	 that	
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the	process	of	generating	cancer	cell	lines	results	in	major	and	irreversible	alterations	





medicine	 applications.	 Novel	 approaches,	 such	 as	 short-term	 primary	 cultures	 or	




in	 the	 application	 of	 more	 advanced	 preclinical	 cancer	 models	 including	 patient	
derived	 tumor	 xenografts	 (PDX)	 as	 well	 as	 genetically	 engineered	 mouse	 (GEM)	
models.		PDX	models	are	not	new,	and	studies	conducted	in	the	80s	already	showed	a	
high	 degree	 of	 correlation	 between	 clinical	 response	 to	 cytotoxic	 agents	 in	 adult	
patients	with	 lung	cancer	and	 response	 to	 the	same	agent	 in	PDX	models	generated	
from	 these	 patients	 (7).	 Similar	 observations	 were	 made	 in	 studies	 of	 childhood	
rhabdomyosarcomas	 (8).	 In	 addition,	 PDX	 models	 have	 been	 used	 to	 conduct	
preclinical	 phase	 II	 studies	with	 classic	 chemotherapeutics	 (9).	 In	 recent	 years	 there	
has	been	 renewed	 interest	 in	 the	development	of	PDX	models	 from	different	 tumor	
types.	 Indeed,	 these	 models	 are	 becoming	 the	 preferred	 preclinical	 tool	 in	 both	
industry	and	academic	groups	in	an	attempt	to	improve	the	drug	development	process	
(10-12).	 	 Currently,	 there	 are	 several	 collections	 of	 extensively	 characterized	 PDX	
models	 in	 use	 for	 different	 translational	 research	 applications.	 These	 collections	
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broadly	represent	the	complex	clinical	tumor	heterogeneity	and	molecular	diversity	of	
human	 cancers.	 In	 this	 paper	we	 review	 current	methodology	 for	 the	 generation	 of	
PDX	models,	provide	a	summary	of	presently	available	collections	of	these	models,	list	
current	 applications	 and	 major	 contributions	 of	 PDX	models	 to	 cancer	 therapeutics	
and	personalized	medicine,	and	highlight	important	issues	for	the	future	development	
















collections	 currently	 available.	 	 Briefly,	 pieces	 of	 primary	 or	metastatic	 solid	 tumors	
maintained	as	 tissue	 structures	are	collected	by	 surgery	or	biopsy	procedures.	 Some	
studies	 have	 also	 used	 fluid	 drained	 from	 malignant	 ascites	 or	 pleural	 effusions.		
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Tumors	 are	 implanted	 as	 pieces	 or	 single	 cell	 suspensions,	 either	 alone	 or	 in	 some	
studies	 coated	with	matrigel	or	mixed	with	human	 fibroblasts	or	mesenchymal	 stem	
cells.	 	 The	 most	 common	 site	 of	 implantation	 is	 on	 the	 dorsal	 region	 of	 mice	
(subcutaneous	implantation),	although	implantation	in	the	same	organ	as	the	original	
tumor	 may	 be	 an	 option	 (orthotopic	 implantation,	 i.e.	 pancreas,	 oral	 cavity,	 ovary,	
mammary	fat	pad,	brain,	etc.).	In	addition,	independently	of	the	tumor	origin,	several	
approaches	 have	 implanted	 primary	 tumors	 in	 the	 renal	 capsule	 in	 an	 effort	 to	
increase	 engraftment	 success	 rates.	 A	 variety	 of	 mouse	 strains	 having	 different	
degrees	of	immunosuppression	have	been	used	in	these	studies.	Supplementary	Table	
1	lists	the	principal	characteristics	of	the	most	commonly	used	mouse	strains	including	
their	 level	 of	 immune	 suppression	 as	 well	 as	 advantages	 or	 disadvantages.	 For	




faster	 engraftment	 rates	 and	 generation	 of	 models	 that	 better	 recapitulate	 human	
tumors	and	are,	therefore,	more	predictive.	However,	it	is	important	to	mention	that	
very	few	studies	have	properly	addressed	comparative	implantation	methods	for	these	
endpoints.	 	 Studies	 in	which	 PDX	models	 have	 been	 generated	 simultaneously	 from	
primary	 tumors	 and	 metastatic	 lesions	 suggest	 that	 metastases	 have	 a	 higher	
engraftment	 rate	 (14,	 15).	 Defining	 the	 most	 appropriate	 host	 mouse	 strains	 to	
generate	PDX	models	is	an	important	consideration.	It	is	assumed	that	more	severely	




are	 the	preferred	 rodent	 strains	 for	many	groups.	However,	 in	human	breast	 cancer	
(HBC)	where	this	question	has	been	robustly	 interrogated,	 implantation	 in	NOD/SCID	
versus	NSG	mice	yielded	similar	take	rates	(16).	In	addition,	host	supplementation	with	
estradiol	pellets	increased	engraftment	rates	from	2.6	to	21.4	%	while,	for	reasons	that	
are	 unclear,	 co-implantation	 with	 immortalized	 human	 fibroblasts	 decreased	
engraftment	rate	(16).		In	contrast,	in	another	study,	a	mixture	of	irradiated	and	non-
irradiated	 human	 fibroblasts	 provided	 improved	 results	 (17).	 Likewise	 orthotopic	
tumor	 implantation	 ("orthoxenografts",	 (18))	 may	 also	 confer	 a	 translational	
advantage,	 as	 the	 tumor	 develops	 in	 the	 same	 anatomical	 microenvironment.	
Generation	 of	 orthoxenografts	 is	 more	 labor-intensive,	 requires	 complex	 surgery,	 is	
more	 expensive	 and	 often	 requires	 imaging	 methods	 to	 monitor	 tumor	 growth.		
However,	 for	 several	 tumor	 types	 (e.g.	ovarian	cancer	or	 lung	cancer),	 this	approach	
substantially	 increases	tumor	take	rates	(19).	 	 In	this	vein,	orthotopic	 implantation	 in	
the	 testis	 is	 essential	 for	 the	 growth	 of	 testicular	 germ	 cell	 tumors.	 As	 for	 tumor	
implantation	 in	 the	 renal	 capsule,	 it	 yielded	an	 impressive	90	%	engraftment	 rate	 in	
non-small	 cell	 lung	 cancer	 (NSCLC)	 as	 compared	 to	 25%	 following	 subcutaneous	
implantation,	 although	 these	 results	 were	 not	 obtained	 from	 a	 single	 comparative	
study	 (20,	 21).	 Furthermore,	 renal	 cell	 capsule	 implantation	 shortens	 time	 to	






As	mentioned,	 the	 principal	 limitation	 of	 conventional	 pre-clinical	models	 (“in	 vitro“	
cell	 line	studies	as	well	as	 “in	vivo“	xenograft	models	generated	by	 implanting	 these	
cells	 in	 immunodeficient	 mice)	 is	 their	 poor	 predictive	 value	 with	 regard	 to	 clinical	
outcome	(4).		The	reasons	why	conventional	cancer	models	have	such	poor	predictive	
power	are	not	completely	understood.		However,	variations	in	the	basic	biology	of	the	
models	 as	 they	 evolve	 are	 likely	 a	 key	 factor.	 	 The	 process	 of	 adaptation	 to	 in	 vitro	
growth	 conditions	 leads	 to	 changes	 in	 the	 biological	 circuits	 of	 the	 cancer	 cell	 that	
differ	from	the	host	derived	entity.		These	include	modifications	in	key	properties	such	










characteristics	 of	 the	 donor	 tumor	 and	 that	 these	 characteristics	will	 be	maintained	
through	 successive	mouse-to-mouse	 passages	 in	 vivo.	 Table	 2	 summarizes	 the	 data	
from	 different	 studies	 in	 which	 PDX	models	 have	 been	 compared	 to	 donor	 tumors	
using	a	variety	of	methods.		In	general,	these	studies	show	that	PDX	models	retain	the	





are	no	substantial	 changes	between	donor	 tumor	and	 their	corresponding	PDX,	with	
only	 genes	 involved	 in	 the	 stromal	 compartment	 and	 immune	 function	 being	 less	
represented	 in	 models,	 due	 to	 the	 replacement	 of	 the	 human	 stroma	 by	 murine	
elements.		Indeed,	using	unsupervised	clustering	analysis,	paired	donor	tumor	and	PDX	
model	 cluster	 together	 in	most	of	 the	 studies.	 	Analyses	of	 copy	number	alterations	
(CNAs)	 and	 exome	 sequencing	 data	 also	 show	 extraordinary	 concordance	 between	




tumors,	 lymphocytes	 and	 PDX)	 in	 breast	 cancer,	 showing	 that	 PDX	 have	 relatively	
stable	genomes	without	a	significant	accumulation	of	DNA	structural	rearrangements	
but	with	some	enrichment	for	PDX-unique	single-nucleotide	variants	(22).		These	PDX-
unique	 mutations	 could	 be	 the	 result	 of	 adaption	 to	 transplantation	 into	 the	 new	
microenvironment,	but	could	also	be	present	 in	 the	original	 tumor	below	detectable	
limits.	A	study	showed	that	many	CNA	changes	found	 in	sarcoma	PDX	are	frequently	
observed	in	sarcoma	patients,	suggesting	that	xenografts	may	in	some	way	represent	
the	 genomic	 rearrangement	 intrinsic	 to	 tumor	 progression	 (23).	 This	 was	 also	
suggested	 in	 another	 study	 describing	 that	 many	 of	 the	 mutations	 detected	 in	 the	
breast	 PDX	 were	 also	 observed	 in	 brain	 metastases	 derived	 from	 the	 same	 patient	
(24).	 Furthermore,	 mouse-to-mouse	 propagation	 does	 not	 substantially	 change	 the	












is	 to	 focus	 on	 well-known	 disease-based	 genomic	 alterations	 rather	 than	 directly	
comparing	 individual	 donor	 versus	 PDX	 characteristics.	 	 In	 PDX	models	 of	 squamous	
cell	carcinoma	of	the	head	and	neck	(SCCHN)	for	example,	the	prevalence	of	TP53	and	
NOTCH	mutations	 is	 similar	 to	 those	 reported	 in	human	 tumors	 (25).	 	 Similar	 results	
have	been	observed	in	colorectal	cancer	(CRC)	and	pancreatic	cancer	(PDAC)	models	in	
which	 the	 frequency	 of	mutations	 in	 genes	 such	 as	TP53	 or	 RAS	 closely	mirrors	 the	
frequency	 of	 these	 mutations	 in	 human	 samples	 (26,	 28,	 29).	 In	 HBC	 PDX	 models,	
several	studies	using	gene	expression	profiles	have	shown	that	intrinsic	breast	cancer	
phenotypes	are	well	represented	and	in	concordance	with	the	original	tumors	(16,	30,	
31).	 Nevertheless	 ER+	 subtypes	 are	 under-represented,	 in	 particular	 the	 recently	






A	 complementary	 approach	 to	 determine	 the	 value	 of	 PDX	models	 in	 cancer	
research	 (discussed	and	 illustrated	below)	 is	by	analyzing	 the	predictive	value	of	 the	
data	obtained	from	PDX	studies	with	regards	to	drug	efficacy,	biomarker	analysis,	and	
patient	outcome.	 In	this	sense,	a	similar	 level	of	activity	as	observed	 in	the	clinic	has	
consistently	been	shown	in	studies	in	which	clinically	applied	drugs	or	regimens	have	
been	 tested	 in	 PDX	 models.	 Table	 3	 provides	 a	 summary	 of	 studies	 in	 which	 PDX	
models	from	different	cancer	types	have	been	treated	with	agents	used	in	the	clinical	
care	of	these	patients.		While	the	analysis	of	data	is	complicated	by	different	response	
criteria	used,	 in	general	 there	 is	 remarkable	similarity	between	the	activity	of	agents	
such	 as	 cetuximab	 in	 CRC	 models	 and	 gemcitabine	 in	 PDAC	 models	 and	 respective	
clinical	trial	data	(28,	29,	33).	Of	even	greater	relevance	is	the	remarkable	one	to	one	
concordance	 in	 studies	 that	 compare	 the	 individual	 donor	 patient	 response	 to	
conventional	anticancer	agents	with	that	of	his/her	PDX	(16,	21,	33,	34).		Furthermore,	
analysis	 of	 clinically	 validated	 biomarkers	 such	 as	KRAS	mutations	 and	 resistance	 to	
EGFR	 inhibitors	 in	 PDX	 studies	 reached	 the	 same	 conclusions	 as	 clinical	 trials,	 as	
discussed	 in	more	detail	below	(28).	Finally,	emerging	studies	 in	which	patients	have	
been	treated	with	drugs	selected	for	their	activity	against	their	PDX	counterparts	show	








success	 rate	 of	 new	 agents	 (36).	 Many	 compounds	 are	 advanced	 to	 large	 phase	 III	
studies,	which	consume	considerable	resources,	to	end	up	failing	because	of	a	lack	of	
efficacy.	 	 Part	 of	 the	 reason	 for	 these	 poor	 results	 is	 that	 conventional	 preclinical	
models	 utilized	 to	 screen	 new	 agents	 for	 clinical	 development	 have	 poor	 predictive	
value	(4).	In	addition,	new	drugs	were	tested	but	biomarkers	for	these	particular	drugs	
were	not	 included	 in	 these	 studies	 in	 the	absence	of	 suitable	biomarkers	 for	patient	
selection	and	response	monitoring.	Thus,	strategies	to	diminish	this	high	attrition	rate	










with	 those	observed	 in	 the	clinic,	both	 for	 targeted	agents	and	 for	classic	cytotoxics.		
For	 example,	 an	 extensive	 analysis	 of	 the	 EGF	 receptor	 inhibitor	 cetuximab	 in	 47	
unselected	CRC	PDX	models	showed	a	10.6	%	response	rate,	which	is	identical	to	the	
response	rate	observed	with	this	agent	in	patients	with	this	disease	(28).		Similar	data	




phase	 I	 trials	 (37).	 In	 RCC,	 PDX	 models	 showed	 response	 to	 the	 mTOR	 inhibitor	
sirolimus	and	the	angiogenesis	inhibitors	sunitinib	and	dovitinib,	but	not	to	erlotinib	as	
was	also	observed	in	clinical	trials	(15).	 	With	regards	to	conventional	chemotherapy,	
studies	 in	NSCLC,	HBC,	CRC	and	PDAC	demonstrated	 that	 response	 rates	 to	clinically	
used	agents	such	as	paclitaxel,	carboplatin,	gemcitabine,	5-fluorouracil,	irinotecan	and	
adriamycin,	 among	 others,	 are	 comparable	 between	 PDX	 models	 and	 clinical	 data	
(Table	3).			
	





with	 advanced	 PDAC	 in	 a	 randomized	 phase	 III	 study,	 and	 is	 likely	 to	 become	 a	
standard	of	care	in	this	setting	(38).	Likewise,	failure	to	exert	antitumor	efficacy	in	PDX	






One	 critical	 aspect	 of	 large	 preclinical	 studies	 in	 PDX	models	 is	 that	 they	 not	
only	 help	 to	 prioritize	 potential	 clinical	 indications,	 but	 they	 may	 also	 facilitate	 the	
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identification	 of	 potential	 drug	 efficacy	 biomarkers.	 The	 concordance	 between	 PDX	




Similar	 data	 were	 observed	 in	 NSCLC	 (21).	 In	 fact,	 it	 could	 be	 argued	 that	 if	 these	
preclinical	studies	had	been	conducted	prior	or	in	parallel	to	the	clinical	development	
of	cetuximab,	the	discovery,	validation	and	approval	of	KRAS	mutation	as	a	marker	of	
resistance	 would	 have	 been	 expedited.	 In	 PDAC,	 PDX	 studies	 with	 gemcitabine	
identified	expression	of	 the	gemcitabine	activating	enzyme	deoxycytidine	kinase	as	a	
predictor	 of	 drug	 efficacy.	 A	 subsequent	 analysis	 of	 this	 marker	 in	 clinical	 samples	
confirmed	 these	 results	 (26,	 41).	 Likewise,	 PDX	 models	 have	 been	 used	 to	 identify	
metabolic	as	well	as	imaging	biomarkers	(42,	43).	
	
Equally	 important	 is	 the	 discovery	 of	 resistance	 biomarkers	 that	may	 help	 to	
design	 combination	 clinical	 trials.	 In	CRC	 it	 has	been	 shown	 that	 tumors	 resistant	 to	
EGFR	inhibition	harbor	amplifications	of	other	genes	such	as	HER2	and	MET	 (28,	44).	
Preclinical	 combination	 studies	with	 agents	 targeting	 these	 genes	 showed	promising	
preclinical	 efficacy	 resulting	 in	 clinical	 translation.	 Likewise,	 in	 SCCHN,	 activating	
mutations	 in	 the	 PIK3CA	 gene	 confer	 resistance	 to	 EGFR	 inhibitors	 that	 can	 be	
modulated	by	agents	that	inhibit	the	PI3K	pathway	(25).		PDX	models	are	also	versatile	
tools	 for	 simulating	 resistance	 when	 exposed	 to	 treatment	 strategies	 used	 in	 the	
clinical	setting.	This	has	been	shown	for	example	in	ovarian	cancer,	in	which	prolonged	
exposure	 to	 cisplatin	 results	 in	 induction	 of	 resistance	 to	 this	 agent	 in	 a	 platinum-
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sensitive	model,	similar	to	what	is	observed	in	the	clinical	setting.		This	model	has	been	
used	 to	 explore	 new	 agents,	 with	 a	 goal	 to	 select	 drugs	 to	 be	 tested	 in	 platinum-
resistant	 patients	 such	 as	 the	 DNA	 minor	 groove	 binder	 lurbinectedin	 (18).	
Interestingly,	 cisplatin-sensitive	 and	 -resistant	 ovarian	 orthoxenografts	 recapitulate	
characteristic	 features	 of	 primary	 human	 tumor	 response,	 such	 as	 the	
histopathological	tumor	regression	criteria	associated	with	patient	treatment	response	








design.	 	 This	 is	 perhaps	 best	 illustrated	 in	 studies	 with	 cancer	 stem	 cell	 (CSC)	
therapeutics	such	as	inhibitors	of	the	Sonic	Hedgehog,	Nodal/Activin,	TGFβ	and	Notch	
pathways	 (46-49).	 In	 PDX	 studies,	 these	 agents	 failed	 to	 induce	 synergistic	 tumor	
regression	 responses	 when	 combined	 with	 chemotherapy	 but	 resulted	 in	 tumor	
growth	 delay	 and,	 importantly,	 in	 a	 decrease	 in	 tumor	 initiation	 and	 relapse.	 In	
addition,	 in	 re-implantation	 studies,	 it	 was	 shown	 that	 administration	 of	 an	 agent	










studies	 to	 help	 select	 populations	 of	 patients	 most	 likely	 to	 be	 sensitive	 to	 a	 new	
agent,	as	well	as	to	prioritize	the	development	of	new	biomarkers.		Figure	1	depicts	a	





advantages	 of	 the	 existing	 PDX	model	 collections	 is	 that	 they	have	been	extensively	
characterized	at	the	histological,	molecular	and	genomic	level.	 	 	Based	on	the	type	of	
agent,	 studies	 can	 be	 adapted	 to	 test	 single	 agents	 or	 clinically	 meaningful	
combinations,	 using	 appropriate	 endpoints	 such	 as	 response	 rate	 (short-response	
assay)	or	 tumor	growth	delay	 (long-term	response).	Agents	 showing	activity	 in	 initial	
screens	 can	 be	 further	 studied	 in	 a	 larger	 group	 of	 models	 using	 statistical	
methodologies	similar	to	two-stage	clinical	trial	design.		Once	again,	the	availability	of	
a	 larger	 collection	 of	 models	 through	 the	 collaboration	 of	 academic	 and	 non-profit	
organizations	would	enable	these	 larger	screens.	 	Biological	and	genetic	comparisons	





Once	 a	 drug	 enters	 clinical	 trials	 there	 are	 limited	 opportunities	 to,	 on	 a	 real-time	
basis,	 analyze	 and	 integrate	 information	 that	may	 be	 useful	 for	 the	 development	 of	
that	agent	(50).		Even	in	studies	that	select	patients	based	on	molecular	abnormalities	
and	 that	 incorporate	 tumor	 tissue,	 normal	 tissue	 and	 imaging-based	
pharmacodynamic	 endpoints,	 there	 are	 few	 options	 for	 real-time	 integration	 and	
exploitation	of	the	observed	information	in	the	trial.		This	is	in	part	due	to	the	intrinsic	
nature	of	clinical	trials	in	which	patients	are	treated	with	one	drug	or	regimen	at	a	time	





To	 solve	 some	 of	 these	 issues,	 the	 concept	 of	 co-clinical	 trials	 has	 been	
proposed.	 	 In	 their	original	 format,	 these	 studies	 refer	 to	 the	use	of	GEM	models	of	
cancer	to	determine	patient	selection	strategies	as	well	as	to	discover	mechanisms	of	
resistance	 to	 treatment	 approaches	 (51,	 52).	 PDX	 models	 have	 been	 used	 in	 this	
context	in	parallel	studies	in	rodent	models	and	patients,	and	have	indeed	been	useful	
in	identifying	potential	biomarkers	(39,	53).		Moreover,	PDX	models	may	also	be	used	
in	another	application	of	 the	 co-clinical	 trial	 concept,	 as	depicted	 in	Figure	2.	 In	 this	
approach,	 a	 personalized	 PDX	model,	 so-called	 ‘Avatar’	model,	 is	 developed	 from	 a	
patient	 enrolled	 in	 a	 clinical	 trial	 and	 treated	with	 the	 same	experimental	 agents	 to	
emulate	 clinical	 response.	 	 This	 strategy	 permits	 assessment	 of	 drug	 response	
simultaneously	 in	the	patient	and	mouse	model,	providing	an	 interesting	platform	to	
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using	 these	models	 emerges	 from	 studies	 such	 as	 those	 listed	 in	 Table	 3	 that	 have	
demonstrated	 a	 remarkable	 correlation	 between	 drug	 response	 in	 PDX	models	 and	
clinical	 response.	 In	 NSCLC	 for	 example,	 PDX	 models	 have	 been	 used	 to	 test	 the	
efficacy	of	three	of	the	most	commonly	used	first-line	chemotherapy	regimens	in	this	
setting.		The	results	of	this	study	show	that	approximately	two	thirds	of	NSCLC	patients	
is	 sensitive	 to	 first-line	 chemotherapy	 while	 one	 third	 is	 resistant.	 Interestingly,	
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patients	 are	not	 sensitive	 to	 all	 regimens	equally	 and	 some	patients	 are	 sensitive	 to	
one	but	resistant	to	another,	suggesting	that	there	is	potential	to	personalize	regimen	
selection	(20).		In	another	study,	investigators	used	Avatar	models	from	patients	with	
advanced	 cancer	 to	 screen	 a	 large	 battery	 of	 anticancer	 agents	 and	 select	 the	most	
effective	agent	to	treat	the	donor	patient.		The	results	of	this	trial	show	that	when	all	
factors	 involved	 are	 correctly	 aligned,	 the	 response	 in	Avatars	 and	patients	 is	 highly	
correlated.		However,	in	most	patients	the	approach	is	not	feasible	for	reasons	such	as	
failure	of	the	tumor	to	engraft,	lack	of	effective	agents,	and	length	of	time	required	for	






revolution	 in	 cancer	 genetics	 is	 permitting,	 for	 the	 first	 time,	 the	 gathering	 of	






PDX	models	may	now	be	useful	 in	 this	 setting	 as	 they	 facilitate	 testing	of	 candidate	





long	 time	 to	 be	 established	 and	 characterized,	 an	 alternative	 to	 the	 Avatar	 strategy	
could	 be	 to	 orientate	 treatment	 choice	 based	 on	 drug	 response	 of	 a	 similar	 PDX.	
Primary	 tumors	 or	 metastases	 biopsies	 would	 be	 molecularly	 characterized	 and	
compared	to	available	PDX	collections	from	the	same	pathology,	for	which	responses	








addressed	 to	 improve	 their	 use	 in	 translational	 cancer	 research.	 	 Some	 of	 these	
limitations	are	technical	in	nature	and	include	several	issues,	such	as	(i)	consideration	
of	 the	 most	 appropriate	 tissue	 from	 which	 to	 generate	 a	 PDX	 model	 and	 the	
processing	 of	 this	 tissue.	 Most	 of	 the	 published	 studies	 have	 relied	 on	 surgical	
specimens	 that	 naturally	 provide	 large	 quantities	 of	 tissues.	 While	 this	 approach	 is	
useful	 to	 generate	 PDX	 collections,	 smaller	 samples,	 such	 as	 tumor	 biopsies	 or	 fine	
needle	 aspirations	 are	 better	 suited	 for	 personalized	medicine	 applications.	 (ii)	 It	 is	
important	 to	 define	 the	 best	 strategy	 of	 engraftment	 in	 mice	 (subcutaneous	 vs.	




a	 PDX	model	 ready	 for	 a	 preclinical	 study,	 a	 time	 frame	 that	many	 patients	 do	 not	
have.	 (iv)	 Another	 problem	 is	 engraftment	 failure	which	 is	 still	 high	 for	 some	 tumor	
types	 with	 particular	 phenotypes,	 such	 as	 hormone	 receptor	 positive	 HBC.	 	 For	
personalized	medicine	 strategies	 it	 is	mandatory	 to	 improve	 tumor	 take	 rates	 to	 an	
acceptable	60-70%,	this	being	one	of	the	main	aspects	requiring	improvement.		This	is	
not	only	 a	problem	 in	personalized	medicine,	 as	most	patients	do	not	have	a	 linked	
PDX	model,	but	also	 in	drug	screening	studies	as	current	PDX	collections	are	skewed	










Another	 critical	 aspect	 is	 the	 substitution	of	 human	 tumor	by	murine	 stroma	
throughout	tumor	growth	in	mice.	 	 In	different	studies	 in	which	this	aspect	has	been	
addressed,	 it	has	been	consistently	shown	that	the	human	cancer	stroma	included	in	


















the	general	 impression	that	more	aggressive	tumors	have	higher	take	rate.	 	 In	breast	
cancer	for	example,	hormone	receptor	negative	tumors	have	a	higher	take	rate	than	
hormone	sensitive	tumors	and	are	overrepresented	in	the	existing	PDX	collections	(16,	
30,	 34).	 	 HBC,	 RCC,	 PDAC	 and	 uveal	 melanoma	 patients	 whose	 tumors	 successfully	








more	 specific	 genes	 and	drug	 targets.	 	 In	 that	 sense,	 some	 studies	have	 shown	 that	
there	are	discrepancies	in	the	expression	of	selected	drug	targets	and	subtle	variations	
in	 the	 expression	 of	 gene	 signatures	 reflecting	 stromal,	 immune	 infiltrate	 or	
angiogenesis	 components.	 	 Indeed,	 several	 studies	 have	 reported	 that	 the	 gene	






and	 using	 them	 for	 different	 cancer	 research	 applications	 (11,	 12).	While	 there	 has	
been	 important	progress	 in	 the	 field,	 there	are	several	 crucial	areas	 that	will	benefit	
from	 additional	 research.	 These	 include	 such	 diverse	 issues	 as:	 implantation	
procedures,	 consideration	 of	 mouse	 host	 strain,	 post	 engraftment	 manipulations,	
robust	application	of	translational	imaging	modalities	in	the	assessment	of	PDX	models	
towards	 the	 elucidation	 of	 imaging	 response	 biomarkers,	 and	 nomenclature	 and	
harmonization	 in	 study	 design	 and	 reporting.	 Furthermore,	 because	 of	 significant	








best	 preservation	 media,	 the	 need	 to	 add	 other	 components	 such	 as	 matrigel	 or	
mesenchymal	 cells,	 site	 of	 implantation	 (subcutaneous,	 orthotopic	 or	 renal	 cell	
capsula),	 and	 time	spent	on	processing	 the	 specimen	 for	better	 results	are	currently	
unknown.		Of	major	importance,	particularly	for	personalized	medicine	applications,	is	
the	development	of	methods	 to	 increase	engraftment	 rates	and	 to	generate	models	
from	difficult-to-engraft	cancer	types	such	as	prostate	or	hormone	dependent	HBC.		Of	
great	interest	in	this	sense	are	newer	three-dimensional	models	of	glioblastoma,	CRC	
and	 HBC	 for	 example.	 These	 tissue-originated	 spheroids	 are	 generated	 by	 digesting	
and	growing	primary	tumor	cells	under	controlled	culture	conditions	(62).	 	Spheroids	






lines	 to	 facilitate	 high-throughput	 drug	 screening	 and	 functional	 studies	 (65).		
However,	 as	 discussed	 above,	 any	 ex-vivo	 manipulation	 may	 pre-empt	 significant	




and	 intra-individual	 manner	 and	 that	 there	 is	 a	 genetic	 evolution	 in	 cancer	 as	 the	
tumor	progresses	(66-68).	Thus,	a	PDX	model	generated	from	one	individual	lesion	at	a	
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single	 time	point	 is	 indeed	a	 snapshot	 view	of	 a	 tremendously	dynamic	process	 and	
may	not	be	representative	of	the	full	diversity	of	the	disease.	Furthermore,	the	process	
of	 PDX	 generation,	 as	 discussed	 in	 detail	 above,	 selects	 for	more	 aggressive	 tumors	
and	likely	for	more	aggressive	clones,	with	metastatic	features,	within	the	tumor.	 	At	
present,	 there	are	no	solutions	 to	 this	 issue.	 	However,	 recent	studies	attempting	 to	
generate	PDX	models	from	circulating	tumor	cells	have	shown	promising	early	results	





tumors	before,	 during	 and	after	 treatments,	 as	 it	 is	 being	performed	nowadays,	will	
also	 result	 in	 novel	 PDX	 models	 from	 paired	 clinically	 drug-sensitive	 and	 -resistant	
tumors.		
	
One	 key	 aspect	 in	 PDX	 research	 is	 the	 host	 mouse	 model	 used.	 	 With	 the	
premise	that	 immunodeficient	hosts	are	required	to	allow	engraftment,	 investigators	
have	 used	 different	mouse	 strains	 to	 generate	 PDX	 collections.	 	 These	 strains	 differ	
with	 regards	 to	 their	 immune	 system	 deficiencies	 and	 provide	 different	 permissive	
environments	 (Supplementary	 Table	 1).	 The	 prevailing	 notion	 that	 a	more	 severely	
immunodeficient	mouse	 is	a	better	host	has	not	been	properly	assessed.	 	While	 this	
question	 may	 not	 be	 relevant	 for	 small-scale	 experiments,	 large	 preclinical	 studies,	
which	use	hundreds	of	mice,	would	benefit	from	the	use	of	cheaper	and	less	delicate	
strains.	 Of	 major	 interest,	 however,	 is	 the	 development	 of	 mouse	 models	 with	
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reconstituted	immune	systems	from	the	donor	individual,	or	models	able	to	replicate	
human,	 rather	 than	 murine	 stroma	 (71).	 A	 “personalized	 immune”	 mouse,	 with	 a	






Another	 critical	 requirement	 is	 the	ability	 to	non-invasively	 and	 longitudinally	
monitor	PDX	tumor	growth	kinetics	and	response	to	therapies.		Small	animal	imaging	
techniques	such	as	computed	tomography,	magnetic	resonance	imaging	and	positron-
emission	 tomography	 allow	 for	 detailed	 appraisal	 of	 tumor	 anatomy,	 vascularization	
and	metabolic	activity	(72).	Nevertheless	these	approaches	are	limited	with	respect	to	
high-throughput	 implementation,	 require	 costly	equipment	and	 infrastructure,	and	a	
high	 level	 of	 technical	 expertise.	 Conversely,	 bioluminescence	 imaging	 (BLI)	 requires	
ectopic	transduction	of	a	light-emitting	enzyme	(usually	luciferase)	in	tumor	cells,	but	
represents	a	cost-effective	and	relatively	high	throughput	and	facile	preclinical	imaging	
modality	 (73).	 Recent	 studies	 have	 reported	 efficient	 expression	 of	 exogenous	
proteins,	 including	luciferase,	by	infecting	patient	derived	tumor	cell	suspensions	and	
spheroid	 cultures	 with	 lentiviral	 particles	 (74).	 While	 these	 advances	 attest	 to	 the	





Efforts	 to	 harmonize	 and	 standardize	 study	 design	 and	 data	 analysis	 are	 also	
needed.	 	 For	 PDX	 preclinical	 studies	 to	 be	 fully	 integrated	 in	 clinical	 development	
pipelines,	there	first	needs	to	be	a	consensus	in	the	design	of	preclinical	studies.		This	
includes	areas	such	as	the	number	of	models	representing	the	tumor	heterogeneity	of	
the	majority	of	 tumor	 types,	and	 the	number	of	mice	per	model	 required	 for	 robust	
statistical	 interrogation,	 as	 per	 a	 clinical	 trial.	 Another	 important	 question	 is	 the	
homogeneity	of	the	batch	of	mice	in	which	a	drug	will	be	assayed,	important	when	a	
large	number	of	mice	are	needed.		A	key	question	is	the	efficacy	endpoint	selected	and	




selected	 endpoint,	 a	 consensus	 is	 needed	 in	 reference	 to	 the	 level	 of	 activity	
considered	sufficient	to	advance	an	agent	to	clinical	development.			
	
		 As	 the	 number	 of	 groups,	 both	 in	 industry	 and	 in	 academia,	 working	 on	
developing	 PDX	 collections	 increases,	 efforts	 to	 develop	 collaborative	 networks	 are	
ongoing.	 These	 networks	will	 likely	 house	 thousands	 of	models	with	well-annotated	
biological,	 clinical	 and	 drug	 response	 data.	 With	 proper	 confidentiality	 and	 data	
protection	 systems,	 this	 information	 can	 be	 shared	 to	 permit	 rapid	 assessment	 of	
model	 availability,	 which	 will	 be	 particularly	 important	 for	 rare	 molecularly-defined	
tumor	 types.	 Furthermore,	 these	 networks	 will	 allow	 the	 conduction	 of	multicenter	




In	 that	 sense,	 within	 Europe	 a	 consortium	 of	 centers	 having	 interest	 and	
significant	 expertise	 in	 PDX	 models,	 has	 now	 emerged:	 EurOPDX	 is	 an	 initiative	 of	
translational	and	clinical	researchers	across	Europe	having	the	common	goal	to	create	
a	 network	 of	 clinically	 relevant	 and	 annotated	 models	 of	 human	 cancer,	 and	 in	
particular	 PDX	models.	 The	 primary	 goal	 of	 our	 initiative	 is	 to	 share	 PDX	models	 in	
diverse	cancer	pathologies,	in	order	to	constitute	a	unique	collection	reproducing	the	





and	 integrative	 systems-based	 analyses	 developed	 to	 elucidate	 novel	 therapeutic	
strategies	 and	 uncover	 predictive	 biomarkers	 for	 personalized	 cancer	 treatment.	
Annotation	of	the	models	will	 include	anatomo-pathological	data,	clinico-pathological	
data	 from	 the	 patients	 the	 PDX	 were	 derived	 from,	 deep	 molecular	 profiling	 in	
particular	with	gene	expression,	copy	number	alterations	and	proteomics	platforms,	as	
well	 as	 pharmacogenomic	 data	 corresponding	 to	 current	 anticancer	 therapies.	
Additional	 technologies	 such	 as	 imaging	 are	 increasingly	 being	 used	 and	 the	 ideal	
database	will	also	include	such	data	as	well	as	scanned	images	of	pathology	slides	(75).		
In	 this	 way	 the	 Consortium	 will	 be	 able	 to	 quickly	 include	 any	 newly	 developed	











as	 a	 prelude	 for	 prospective	 clinical	 trials	 in	 humans.	 The	 consortium	 will	 be	 in	
absolute	 compliance	 with	 European	 rules	 for	 the	 use	 of	 experimental	 animals.	 A	
coordinated	 and	 rational	 design	 of	 the	 experiments,	 troubleshooting	 and	 sharing	 of	
positive	and	negative	results	across	the	various	centers	will	enable	a	reduction	in	the	
overall	number	of	experimental	animals	utilized	and	optimize	the	use	of	each	precious	
patient	 sample,	 avoiding	 unnecessary	 replicas	 of	 experiments,	 while	maximizing	 the	
statistical	significance	and	robustness	of	the	data.	
	





companies	 and	 SMEs,	 the	 EurOPDX	 initiative	will	 accelerate	 the	emergence	of	 novel	
therapeutic	strategies	with	a	real	impact	on	quality	of	life	and	overall	survival	of	cancer	






Over	 the	 last	 decade	 there	 has	 been	 an	 interest	 in	 developing	 and	 characterizing	




integrated	 in	personalized	medicine	strategies.	 	 It	 is	envisioned	 that	PDX	models	will	
eventually	play	a	broader	role	 in	the	drug	development	process	and	become	a	must-
have	element	in	that	process.	At	present,	however,	there	are	still	some	critical	issues	
that	 must	 be	 addressed	 to	 make	 this	 platform	 more	 useful	 and	 informative.	 	 This	
includes	 increasing	the	take	rate	and	time	to	model	generation,	recapitulation	of	the	
human	stroma	and	immune-related	elements,	as	well	as	strategies	to	develop	models	
more	 representative	 of	 different	 cancer	 entities,	 tumor	 heterogeneity	 and	
chemorefractory	 patients.	 Finally,	 initiatives	 to	 harmonize	 nomenclature,	 study	
designs	 and	 procedures	 are	 needed.	 We	 propose	 that	 the	 new	 European	 EurOPDX	
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or	 in	 parallel	 to	 phase	 I	 safety	 and	 pharmacology	 testing.	 Models	 can	 be	 selected	
based	 on	 tumor	 types	 or	 on	 predefined	 molecular	 subtypes	 if	 that	 information	 is	
known	and	of	interest,	or	both.		We	propose	a	two-step	approach.	In	Step	1,	a	limited	
number	of	models	can	be	tested	with	the	agent	at	doses	and	schedules	known	to	be	
effective	 and	 pharmacologically	 active	 in	 earlier	 preclinical	 studies.	 Study	 endpoints	
need	 to	 be	 carefully	 selected	 based	 on	 the	 agent's	mechanism	of	 action.	Data	 from	






A	 new	 version	 of	 the	 co-clinical	 trial	 concept	 is	 presented	 in	 which	 a	 PDX	model	 is	
developed	 from	 a	 patient	 enrolled	 and	 treated	 in	 a	 clinical	 trial	with	 a	 novel	 agent.		
This	approach	permits	to	have	models	with	validated	clinical	outcome	data	that	can	be	







of	 a	 patient	 tumor	 is	 likely	 to	 show	 tens	 of	 potential	 therapeutically	 targetable	
mutations.		Mining	of	genomic-drug	response	databases	such	as	the	CCLE	or	the	NCI60	
as	 well	 as	 knowledge	 of	 these	 mutations	 is	 likely	 to	 result	 in	 several	 potential	
therapeutic	 regimens	 for	a	 given	patient.	 The	Avatar	model	 can	be	used	 to	 test	 and	
rank	these	potential	treatments	to	be	administered	to	the	patient.		A	post	hoc	analysis	














A	model	 for	 personalized	 cancer	 treatment,	 using	 HBC	 as	 an	 example,	 is	 proposed.		
Knowing	the	response	to	treatment	agents	of	genetically	defined	PDX	models	can	be	
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(28)	 CRC	 130	 Metastasis	 Surgery	 Fresh	tumor	pieces		
in	matrigel	
NOD/SCID	 s.c.	 87	%	
(29)	 CRC	 54	 Primary	(35)	
Metastasis	
(19)	
Surgery	 Fresh	tumor	pieces	 Nude	 s.c.	 64	%	
(76)	 CRC	 41	 Primary		 Surgery	 Fresh	tumor	pieces	 Nude	 Orthotopic	 89.1%	
(34)	 HBC	 25	 Primary	 Surgery	 Fresh	tumor	pieces	 Nude	 s.c.	 13	%	





























NSCLC	 32	 Primary	 Surgery	 Fresh	tumor	pieces	
	
NOD/SCID	 Renal	capsule	 90	%	
(33)	 PDAC	 42	 Primary		 Surgery	 Fresh	tumor	pieces			
in	matrigel	
Nude	 s.c.	 61	%	







(77)	 PDAC	 16	 Primary	(11)	
Metastasis	
(5)	
Surgery	 Fresh	tumor	pieces	 Nude	 Orthotopic	 62%	



















































































































































































































































































































































































































































































Cholangiocarcinoma	 6	 Adenocarcinoma:	6	 Primary	tumor:	6	 3	 GEP:	2	
CNA:	2	
Exomic	Sequencing:	2	
Gastric	 7	 Adenocarcinoma:	7	 Primary	tumor:	6	
Metastasis:	1	
7	 -	
Esophagus	 2	 Adenocarcinoma:	2	 Primary	tumor:	1	
Metastasis:	1	
2	 -	
Lymphoma	 3	 Large	B	cell:	3	 -	 3	 -	
Pediatrics	 1	 Hepatoblastoma:	1	 Metastasis:	1	 1	 -	
	
